PP
MDGL icon

Paloma Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Paloma Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,781
Closed -$161K – 2131
2016
Q4 		$161K Buy
+10,781
New +$173K ﹤0.01% 1865
2015
Q2 		– Sell
-551
Closed -$37K – 1880
2015
Q1 		$37K Buy
+551
New +$47.3K ﹤0.01% 1156
2014
Q4 		– Sell
-798
Closed -$84K – 1281
2014
Q3 		$84K Buy
+798
New +$111K ﹤0.01% 911

Other funds holding MDGL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Paloma Partners's MDGL Position: Q1 2017 in Review

Paloma Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2017, closing a stake of 10,781 shares — an estimated $161K sold.

Paloma Partners first reported a position in MDGL in Q3 2014 and held it in 3 quarters. The position peaked at $161K in Q4 2016. 32 funds tracked by Wall St. Rank hold MDGL as of Q1 2017.

  • Paloma Partners reported no remaining Madrigal Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Paloma Partners sold 10,781 Madrigal Pharmaceuticals shares in Q1 2017, an estimated $161K.
  • Paloma Partners first reported a position in Madrigal Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • Paloma Partners's Madrigal Pharmaceuticals position peaked at $161K in Q4 2016.
  • 32 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2017.

Based on Paloma Partners's 13F filing for Q1 2017, filed 15 May 2017.